Evidence map›Paper›PMID 27132513›Full record

ArticleOncogene2016

TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.

H Si, H Lu, X Yang, A Mattox, M Jang, Y Bian, E Sano, H Viadiu, B Yan, C Yau and 14 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 40 citations in OpenAlex.

  1. Reciprocity between p63 and p21 via TNFα/NF-κB signaling in p63-positive salivary duct adenocarcinoma cell.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 4 countries.

H SiTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
H LuTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
X YangTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
A MattoxTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
M JangTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
Y BianTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
E SanoDepartment of Chemistry and Biochemistry, University of California, San Diego, CA, USA.
H ViadiuInstituto de Química, Universidad Nacional Autónoma de México (UNAM), Circuito Exterior, Ciudad Universitaria, Mexico City, MÉXICO.
B YanLKS Faculty of Medicine and School of Biomedical Sciences, LKS Faculty of Medicine and Center of Genome Sciences, The University of Hong Kong, Hong Kong, China.
C YauBuck Institute for Research on Aging, Novato, CA, USA.
S NgDepartment of Biomolecular Engineering, Center for Biomolecular Sciences and Engineering, University of California, Santa Cruz, Santa Cruz, CA, USA.
S K LeeTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
R-A RomanoDepartment of Biochemistry, State University of New York at Buffalo, Center for Excellence in Bioinformatics and Life Sciences, Buffalo, New York, USA.
S DavisCancer Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA.
R L WalkerCancer Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA.
W XiaoDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AK, USA.
H SunBiodata Mining and Discovery Section, National Institute of Arthritis, Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
L WeiClinical Immunology Section, National Eye Institute, NIH, Bethesda, Maryland, USA.
S SinhaDepartment of Biochemistry, State University of New York at Buffalo, Center for Excellence in Bioinformatics and Life Sciences, Buffalo, New York, USA.
C C BenzBuck Institute for Research on Aging, Novato, CA, USA.
J M StuartDepartment of Biomolecular Engineering, Center for Biomolecular Sciences and Engineering, University of California, Santa Cruz, Santa Cruz, CA, USA.
P S MeltzerCancer Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA.
C Van WaesTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
Z ChenTumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
National Institute on Deafness and Other Communication Disorders · USBuck Institute for Research on Aging · USNational Cancer Institute · USUniversity at Buffalo, State University of New York · USUniversity of California, Santa Cruz · USCancer Genetics (United States) · USChinese University of Hong Kong · CNNational Institute of Arthritis and Musculoskeletal and Skin Diseases · USSun Yat-sen University · CNUnited States Food and Drug Administration · USUniversidad Nacional Autónoma de México · MXUniversity of California, San Diego · US

Funding

Cancer Genomics Technology DevelopmentZIABC011091 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MELTZER, PAUL S. · 2009 to 2025
$16.9M
Genomics and Proteomics of Head and Neck CancerZIADC000074 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 2009 to 2022
$11.1M
Pharmaco Response Signatures and Disease MechanismU54HG006097 · NHGRI · HARVARD MEDICAL SCHOOL · PI MITCHISON, TIMOTHY J, SORGER, PETER KARL · 2010 to 2013
$9.7M
NF-kappaB in pathogenesis and therapy of head and neck cancerZIADC000016 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 2009 to 2022
$9.3M
Signal and Transcription Factor Network interactions in Head and Neck CancerZIADC000073 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 2009 to 2022
$9.1M
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)U24CA143858 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI BENZ, CHRISTOPHER, HAUSSLER, DAVID H · 2009 to 2016
$8.9M
BIGDATA: Mid-Scale DCM: DA: ESCE: Discovering Molecular ProcessesR01CA180778 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STUART, JOSHUA MICHAEL · 2013 to 2017
$3.5M
NF-kappaB in pathogenesis and therapy of head and neck cancerZ01DC000016 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 1994 to 2008
$2.9M
New Integrative Pathway Analysis Methods to Predict Biomedical OutcomesR01GM109031 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STUART, JOSHUA MICHAEL · 2014 to 2018
$2.9M
UCSC-Buck Specialized Genomic Data Analysis Center for the Genomic Data Analysis NetworkU24CA210990 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STUART, JOSHUA MICHAEL · 2016 to 2020
$2.2M
Transcriptional control of epidermal differentiationR01AR049238 · NIAMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI SINHA, SATRAJIT · 2004 to 2008
$1.4M
Genomics and Proteomics of Head and Neck CancerZ01DC000074 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 2008 to 2008
$607k
Intramural NIH HHS Z01 DC000016Intramural NIH HHS Z01 DC000073Intramural NIH HHS Z01 DC000074Intramural NIH HHS ZIA DC000073Intramural NIH HHS ZIA DC000074NCI NIH HHS R01 CA180778NCI NIH HHS U24 CA143858NCI NIH HHS U24 CA210990NHGRI NIH HHS U54 HG006097NIAMS NIH HHS R01 AR049238NIGMS NIH HHS R01 GM109031
6 · The paper itself

Abstract

The Cancer Genome Atlas (TCGA) network study of 12 cancer types (PanCancer 12) revealed frequent mutation of TP53, and amplification and expression of related TP63 isoform ΔNp63 in squamous cancers. Further, aberrant expression of inflammatory genes and TP53/p63/p73 targets were detected in the PanCancer 12 project, reminiscent of gene programs comodulated by cREL/ΔNp63/TAp73 transcription factors we uncovered in head and neck squamous cell carcinomas (HNSCCs). However, how inflammatory gene signatures and cREL/p63/p73 targets are comodulated genome wide is unclear. Here, we examined how the inflammatory factor tumor necrosis factor-α (TNF-α) broadly modulates redistribution of cREL with ΔNp63α/TAp73 complexes and signatures genome wide in the HNSCC model UM-SCC46 using chromatin immunoprecipitation sequencing (ChIP-seq). TNF-α enhanced genome-wide co-occupancy of cREL with ΔNp63α on TP53/p63 sites, while unexpectedly promoting redistribution of TAp73 from TP53 to activator protein-1 (AP-1) sites. cREL, ΔNp63α and TAp73 binding and oligomerization on NF-κB-, TP53- or AP-1-specific sequences were independently validated by ChIP-qPCR (quantitative PCR), oligonucleotide-binding assays and analytical ultracentrifugation. Function of the binding activity was confirmed using TP53-, AP-1- and NF-κB-specific REs or p21, SERPINE1 and IL-6 promoter luciferase reporter activities. Concurrently, TNF-α regulated a broad gene network with cobinding activities for cREL, ΔNp63α and TAp73 observed upon array profiling and reverse transcription-PCR. Overlapping target gene signatures were observed in squamous cancer subsets and in inflamed skin of transgenic mice overexpressing ΔNp63α. Furthermore, multiple target genes identified in this study were linked to TP63 and TP73 activity and increased gene expression in large squamous cancer samples from PanCancer 12 TCGA by CircleMap. PARADIGM inferred pathway analysis revealed the network connection of TP63 and NF-κB complexes through an AP-1 hub, further supporting our findings. Thus, inflammatory cytokine TNF-α mediates genome-wide redistribution of the cREL/p63/p73, and AP-1 interactome, to diminish TAp73 tumor suppressor function and reciprocally activate NF-κB and AP-1 gene programs implicated in malignancy.

Indexed as

Binding SitesCarcinoma, Squamous CellCell Transformation, NeoplasticCluster AnalysisConsensus SequenceGene Expression ProfilingGene Expression Regulation, NeoplasticHumansModels, BiologicalNF-kappa BNucleotide MotifsPromoter Regions, GeneticProtein BindingProtein TransportRegulatory Sequences, Nucleic AcidResponse ElementsNF-kappa BTP63 protein, humanTranscription Factor AP-1Transcription FactorsTumor Necrosis Factor-alphaTumor Protein p73Tumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID27132513
PMCPMC5093089
OpenAlexW2346106718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.